These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
300 related articles for article (PubMed ID: 33984327)
1. Tanshinone IIA sensitizes TRAIL-induced apoptosis in glioblastoma through inducing the expression of death receptors (and suppressing STAT3 activation). Zhou X; Lv L; Tan Y; Zhang Z; Wei S; Xiao S Brain Res; 2021 Sep; 1766():147515. PubMed ID: 33984327 [TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA induces TRAIL sensitization of human lung cancer cells through selective ER stress induction. Kim EO; Kang SE; Im CR; Lee JH; Ahn KS; Yang WM; Um JY; Lee SG; Yun M Int J Oncol; 2016 May; 48(5):2205-12. PubMed ID: 26983803 [TBL] [Abstract][Full Text] [Related]
3. Celastrol enhances TRAIL-induced apoptosis in human glioblastoma via the death receptor pathway. Cha Z; Cheng J; Xiang H; Qin J; He Y; Peng Z; Jia J; Yu H Cancer Chemother Pharmacol; 2019 Oct; 84(4):719-728. PubMed ID: 31281953 [TBL] [Abstract][Full Text] [Related]
4. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. Guo L; Fan L; Pang Z; Ren J; Ren Y; Li J; Chen J; Wen Z; Jiang X J Control Release; 2011 Aug; 154(1):93-102. PubMed ID: 21609741 [TBL] [Abstract][Full Text] [Related]
5. Down-regulation of Cbl-b by bufalin results in up-regulation of DR4/DR5 and sensitization of TRAIL-induced apoptosis in breast cancer cells. Yan S; Qu X; Xu C; Zhu Z; Zhang L; Xu L; Song N; Teng Y; Liu Y J Cancer Res Clin Oncol; 2012 Aug; 138(8):1279-89. PubMed ID: 22447040 [TBL] [Abstract][Full Text] [Related]
6. Tanshinone IIA inhibits the growth, attenuates the stemness and induces the apoptosis of human glioma stem cells. Yang L; Guo H; Dong L; Wang L; Liu C; Wang X Oncol Rep; 2014 Sep; 32(3):1303-11. PubMed ID: 24970314 [TBL] [Abstract][Full Text] [Related]
7. Azithromycin enhances anticancer activity of TRAIL by inhibiting autophagy and up-regulating the protein levels of DR4/5 in colon cancer cells in vitro and in vivo. Qiao X; Wang X; Shang Y; Li Y; Chen SZ Cancer Commun (Lond); 2018 Jul; 38(1):43. PubMed ID: 29970185 [TBL] [Abstract][Full Text] [Related]
8. Nuciferine inhibits the progression of glioblastoma by suppressing the SOX2-AKT/STAT3-Slug signaling pathway. Li Z; Chen Y; An T; Liu P; Zhu J; Yang H; Zhang W; Dong T; Jiang J; Zhang Y; Jiang M; Yang X J Exp Clin Cancer Res; 2019 Mar; 38(1):139. PubMed ID: 30922391 [TBL] [Abstract][Full Text] [Related]
9. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH Oncotarget; 2014 Jul; 5(14):5624-36. PubMed ID: 25015549 [TBL] [Abstract][Full Text] [Related]
10. Lanatoside C sensitizes glioblastoma cells to tumor necrosis factor-related apoptosis-inducing ligand and induces an alternative cell death pathway. Badr CE; Wurdinger T; Nilsson J; Niers JM; Whalen M; Degterev A; Tannous BA Neuro Oncol; 2011 Nov; 13(11):1213-24. PubMed ID: 21757445 [TBL] [Abstract][Full Text] [Related]
11. Dovitinib sensitizes hepatocellular carcinoma cells to TRAIL and tigatuzumab, a novel anti-DR5 antibody, through SHP-1-dependent inhibition of STAT3. Chen KF; Chen HL; Liu CY; Tai WT; Ichikawa K; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Mar; 83(6):769-77. PubMed ID: 22230479 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of ataxia telangiectasia mutated kinase activity enhances TRAIL-mediated apoptosis in human melanoma cells. Ivanov VN; Zhou H; Partridge MA; Hei TK Cancer Res; 2009 Apr; 69(8):3510-9. PubMed ID: 19351839 [TBL] [Abstract][Full Text] [Related]
13. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins. Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278 [TBL] [Abstract][Full Text] [Related]
16. Synergistic interactions of chemotherapeutic drugs and tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand on apoptosis and on regression of breast carcinoma in vivo. Singh TR; Shankar S; Chen X; Asim M; Srivastava RK Cancer Res; 2003 Sep; 63(17):5390-400. PubMed ID: 14500373 [TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. Dorsey JF; Mintz A; Tian X; Dowling ML; Plastaras JP; Dicker DT; Kao GD; El-Deiry WS Mol Cancer Ther; 2009 Dec; 8(12):3285-95. PubMed ID: 19996278 [TBL] [Abstract][Full Text] [Related]
18. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Mitsiades N; Poulaki V; Mitsiades C; Tsokos M Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151 [TBL] [Abstract][Full Text] [Related]
19. Suppression of HSP70 expression sensitizes NSCLC cell lines to TRAIL-induced apoptosis by upregulating DR4 and DR5 and downregulating c-FLIP-L expressions. Zhuang H; Jiang W; Zhang X; Qiu F; Gan Z; Cheng W; Zhang J; Guan S; Tang B; Huang Q; Wu X; Huang X; Jiang W; Hu Q; Lu M; Hua ZC J Mol Med (Berl); 2013 Feb; 91(2):219-35. PubMed ID: 22948392 [TBL] [Abstract][Full Text] [Related]
20. Combination of TRAIL and actinomycin D liposomes enhances antitumor effect in non-small cell lung cancer. Guo L; Fan L; Ren J; Pang Z; Ren Y; Li J; Wen Z; Qian Y; Zhang L; Ma H; Jiang X Int J Nanomedicine; 2012; 7():1449-60. PubMed ID: 22619505 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]